• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.

作者信息

Hultcrantz Malin, Kleinman David, Vij Ravi, Escalante Fernando, Delforge Michel, Kotowsky Nirali, Bitetti Jacopo, Boytsov Natalie, Camadoo-O'Byrne Leena, Happ Lindsey Powers, Germain Guillaume, Urosevic Ana, Mahendran Malena, Duh Mei Sheng, Laliberte Francois, Cavo Michele, Lee Hans C

机构信息

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY.

Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY.

出版信息

Haematologica. 2025 Mar 1;110(3):753-757. doi: 10.3324/haematol.2024.285893.

DOI:10.3324/haematol.2024.285893
PMID:39415693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11877074/
Abstract
摘要

相似文献

1
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.贝兰他单抗莫福汀单药治疗复发或难治性多发性骨髓瘤：美国一项真实世界观察性研究
Haematologica. 2025 Mar 1;110(3):753-757. doi: 10.3324/haematol.2024.285893.
2
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.EMA 审查贝兰他单抗mafodotin（Blenrep）治疗成人复发/难治性多发性骨髓瘤。
Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.
3
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.单药贝兰他单抗mafodotin 与泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性（DREAMM-3）：一项开放标签、随机、3 期研究。
Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
4
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.真实世界中贝兰他单抗治疗复发/难治性多发性骨髓瘤的经验：一项多中心回顾性研究。
Br J Haematol. 2023 Jan;200(1):45-53. doi: 10.1111/bjh.18479. Epub 2022 Oct 7.
5
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
6
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.DREAMM-11，第2部分：马法兰氟唑帕利联合疗法在复发/难治性多发性骨髓瘤中的日本I期试验
Int J Hematol. 2025 Feb;121(2):174-186. doi: 10.1007/s12185-024-03889-8. Epub 2024 Dec 24.
7
Belantamab mafodotin for the treatment of multiple myeloma.贝兰他单抗马妥昔单抗用于多发性骨髓瘤的治疗。
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146.
8
Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.在复发或难治性多发性骨髓瘤的日本患者中，贝兰他单抗mafodotin 单药治疗的安全性、药代动力学和疗效：DREAMM-11。
Int J Hematol. 2023 Nov;118(5):596-608. doi: 10.1007/s12185-023-03652-5. Epub 2023 Sep 5.
9
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.真实世界中贝兰他单抗mafodotin 单药治疗三药难治性多发性骨髓瘤的疗效和安全性。
Int J Mol Sci. 2023 Jul 23;24(14):11829. doi: 10.3390/ijms241411829.
10
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.贝兰他单抗莫福汀治疗复发或难治性多发性骨髓瘤的临床历程：药物研发经验教训
Blood Cancer J. 2025 Feb 7;15(1):15. doi: 10.1038/s41408-025-01212-0.

引用本文的文献

1
Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study.优化贝兰他单抗莫福汀治疗复发或难治性多发性骨髓瘤：真实世界回顾性研究中剂量调整对不良事件和血液学反应的影响
Cancers (Basel). 2025 Jul 19;17(14):2398. doi: 10.3390/cancers17142398.
2
Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study.用贝兰他单抗莫福汀治疗的多发性骨髓瘤患者的真实世界特征和结局：一项德国索赔数据研究。
Ann Hematol. 2025 May 31. doi: 10.1007/s00277-025-06427-6.

本文引用的文献

1
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.硼替佐米、泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2.
2
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.贝兰他单抗马妥昔单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
3
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.难治性多发性骨髓瘤中贝兰他单抗马妥莫单抗、泊马度胺和地塞米松的疗效：一项 1/2 期试验。
Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4.
4
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.单药贝兰他单抗mafodotin 与泊马度胺联合低剂量地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性（DREAMM-3）：一项开放标签、随机、3 期研究。
Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
5
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.单药贝兰他单抗mafodotin 治疗复发/难治性多发性骨髓瘤患者：DREAMM-2 试验的最终分析。
Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25.
6
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
7
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.新型抗 B 细胞成熟抗原抗体药物偶联物（GSK2857916）选择性诱导多发性骨髓瘤细胞的杀伤。
Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25.